Effects of CPG ODN on biological behavior of PANC-1 and expression of TLR9 in pancreatic cancer

World Journal of Gastroenterology

Volumn 17, Issue 8, 2011, Pages 996-1003

  Wu, Han Qing ^a   Wang, Bo ^a   Zhu, Shi Kai ^a   Tian, Yuan ^a   Zhang, Jing Hui ^a   Wu, He Shui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Biological behavior; Cytosine phosphate guanosine oligodeoxynucleotides 2216; Pancreatic cancer; Toll like receptor 9

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; MATRIGEL; TOLL LIKE RECEPTOR 9;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER TISSUE; CARCINOMA CELL; CELL ADHESION; CELL CULTURE; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMATION; CONTROL GROUP; DOSE RESPONSE; GENE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METASTASIS; MIGRATION; PANCREAS CANCER; PANCREAS CARCINOMA; PROTEIN EXPRESSION; STAINING; TUMOR; WOUND HEALING;

EID: 79955940011     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i8.996     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66
2. Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzese JL. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 2000; 95: 17-31
3. Real FX, Cibrián-Uhalte E, Martinelli P. Pancreatic cancer development and progression: remodeling the model. Gastroenterology 2008; 135: 724-728
4. Tanase CP, Dima S, Mihai M, Raducan E, Nicolescu MI, Albulescu L, Voiculescu B, Dumitrascu T, Cruceru LM, Leabu M, Popescu I, Hinescu ME. Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma. J Mol Histol 2009; 40: 23-29
5. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 2001; 358: 1576-1585
6. Jungert K, Buck A, von Wichert G, Adler G, König A, Buchholz M, Gress TM, Ellenrieder V. Sp1 is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res 2007; 67: 1563-1570
7. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801
8. O'Neill LA. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 2006; 18: 3-9
9. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5: 975-979
10. Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS. Activation of Tolllike receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther 2008; 7: 3642-3653
11. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006; 66: 3859-3868
12. Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 2007; 21: 387-401
13. Theiner G, Rössner S, Dalpke A, Bode K, Berger T, Gessner A, Lutz MB. TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells. Mol Immunol 2008; 45: 244-252
14. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 1996; 19: 1518-1520
15. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-3245
16. Lowenfels AB, Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 2004; 34: 238-244
17. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867
18. Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P, Goldmann T. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 2005; 6: 1
19. Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998; 188: 2335-2342
20. Bendigs S, Salzer U, Lipford GB, Wagner H, Heeg K. CpGoligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. Eur J Immunol 1999; 29: 1209-1218
21. Underhill DM. Toll-like receptors: networking for success. Eur J Immunol 2003; 33: 1767-1775
22. Ahmad-Nejad P, Häcker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002; 32: 1958-1968
23. Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, Giese T, Endres S, Hartmann G. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol 2003; 170: 4465-4474
24. Takauji R, Iho S, Takatsuka H, Yamamoto S, Takahashi T, Kitagawa H, Iwasaki H, Iida R, Yokochi T, Matsuki T. CpGDNA- induced IFN-alpha production involves p38 MAPKdependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors. J Leukoc Biol 2002; 72: 1011-1019
25. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008; 27: 161-167
26. Celetti A, Testa D, Staibano S, Merolla F, Guarino V, Castellone MD, Iovine R, Mansueto G, Somma P, De Rosa G, Galli V, Melillo RM, Santoro M. Overexpression of the cytokine steopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res 2005; 11: 8019-8027
27. Eble JA, Haier J. Integrins in cancer treatment. Curr Cancer Drug Targets 2006; 6: 89-105